Designation of Sebelipase Alfa as an orphan drug by Alexion Pharmaceuticals Australasia Pty Ltd

Overview

The Therapeutic Goods Act 1989, enacted by the Commonwealth Parliament of Australia, serves as the primary piece of legislation regulating therapeutic goods in Australia. This Act was introduced to address the need for a comprehensive regulatory framework governing the quality, safety, efficacy, and timely availability of therapeutic goods in the country. Among its various provisions, the Act facilitates the regulation of drugs, medical devices, and other therapeutic products to protect public health and safety. One notable aspect of the Act is its capacity to designate orphan drugs, which are medications intended for the treatment of rare medical conditions. This mechanism is designed to encourage the development and availability of treatments for conditions that might otherwise lack sufficient incentive for pharmaceutical companies to pursue. In the context of this legislation, Dr. Anthony Gill, acting as the Delegate of the Secretary for the purposes of the Therapeutic Goods Regulations 1990, designated sebelipase alfa as an orphan drug on 14 November 2015. This designation was made to support the treatment of lysosomal acid lipase (LAL) deficiency, a rare genetic disorder. The sponsor for sebelipase alfa, an injectable solution, was Alexion Pharmaceuticals Australasia Pty Ltd. The policy objective behind this designation is to ensure that rare disease treatments receive the necessary regulatory support and incentives to be developed and made available to patients in need.

Scope and Application

The Therapeutic Goods Act 1989, under the auspices of the Therapeutic Goods Administration (TGA) within the Department of Health, designates sebelipase alfa as an orphan drug for the treatment of lysosomal acid lipase (LAL) deficiency. This designation is specifically for a solution for injection form of the drug and applies to the sponsor, Alexion Pharmaceuticals Australasia Pty Ltd. The orphan drug designation is aimed at addressing unmet medical needs by incentivising the development of drugs for rare diseases or conditions that affect a small number of people. This Act applies to pharmaceutical products and therapeutic goods within the Commonwealth of Australia, ensuring that drugs such as sebelipase alfa, which target rare conditions, receive appropriate regulatory support and prioritisation. The geographic and jurisdictional reach of this legislation is national, encompassing all states and territories of Australia. The designation process and its implications are governed by the Therapeutic Goods Regulations 1990, and any further extensions or restrictions of application may be detailed in subordinate instruments issued by the TGA.

Key Provisions

The key provision of this legislative instrument, C2015G01918 (Gazette), designates sebelipase alfa as an orphan drug under section 16J of the Therapeutic Goods Regulations 1990 (Regulations) (1). This designation, made by Dr Anthony Gill, the Delegate of the Secretary, takes effect on 14 November 2015, and applies specifically to the treatment of lysosomal acid lipase (LAL) deficiency (1). Sebelipase alfa is indicated for use in the form of a solution for injection (1). The sponsor of sebelipase alfa, as stated in the legislation, is Alexion Pharmaceuticals Australasia Pty Ltd (1). The designation of sebelipase alfa as an orphan drug imposes several obligations and requirements on the parties involved. Firstly, it signifies that the drug is intended for a rare disease, lysosomal acid lipase (LAL) deficiency, affecting a small population (2). This designation provides a framework for the regulation and marketing of the drug, ensuring it meets specific criteria for orphan drugs, such as the rarity of the condition it treats and the potential benefits to patients (2). Additionally, the sponsor, Alexion Pharmaceuticals Australasia Pty Ltd, must comply with all relevant regulatory requirements to ensure the safety, quality, and efficacy of the drug (2). Under the Therapeutic Goods Act 1989, there are potential civil and criminal consequences for breaches of the regulations pertaining to therapeutic goods. The severity of these penalties can vary depending on the nature and extent of the breach. For example, section 21 of the Act provides for penalties including fines and imprisonment for offences such as manufacturing or supplying therapeutic goods that do not comply with the standards set by the Therapeutic Goods Regulations 1990 (3). In cases of serious or repeated breaches, the maximum penalties can be substantial, reflecting the seriousness of compromising public health and safety through non-compliance with therapeutic goods regulations (3). The exact penalties are detailed in the relevant sections of the Act and Regulations, providing a clear framework for enforcement and compliance.